Methods: Fifty patients were randomly given either TC or placebo for 8 weeks. They were clinically examined and Hb %, TLC, DLC and nasal smear was done.

Results: It was seen that allergic rhinitis was more common in the age group 20–30 years (68%). There were 7 patients in the age group of 31–40 (14%), 6 in 41–50 (12%) and 3 in 51–60 age group (6%). Women were more affected than men (32:18). On analyses of the effect of TC and placebo after 8 weeks of administration on the symptoms of allergic rhinitis, it was seen that there was total relief from sneezing in nearly 82% patients who received TC while in placebo group 80% had no relief at all. In case of nasal discharge, TC showed 100% improvement in nearly 68% while in placebo group only one patient (3%) had such relief. Nasal obstruction was totally cleared in nearly 60% patients who had received TC while nearly 82% patients on placebo had no relief from it. In nasal pruritus, 70% patients of TC group had 100% improvement whereas in placebo group 88% had no relief from this symptom.

Conclusion: TC significantly decreased all symptoms of allergic rhinitis. Nasal smear cytology and leukocyte count correlated with clinical findings. TC was well tolerated.